Lung PD-L1 22C3 (Prior to Pembrolizumab Therapy)

Turnaround Time

5-7 days

General Information

PD-L1 expression analysis is also important in informing first (and second) line anti PD-1 / anti-PD-L1 monoclonal antibody treatment for lung NSCLC. A relatively recent addition to the testing landscape, in 2016, immunohistochemical analysis using companion-diagnostic antibodies specific to the relevant treatments gives a quantitative expression result.

What to send:

  • Paraffin block from biopsy, resection or cell block.
  • Unstained mounted sections at 3μm on Agilent Flex slides - dried at room temperature

PDL1 22C3 Request Form

Notes

Please note tissue handling, tissue fixation, time between cutting and staining and excessive drying can lead to loss of expression. Fixatives containing alcohol should not be used and use of Bouin’s fixative will preclude testing by FISH methods.

A copy of the original Pathology report where possible.

Specifications

  • EQA Status: NEQAS

General Information

General information about the website and its content

Location of Laboratories

Where the laboratories are located and information about the services offered at each laboratory